Use of ciprofloxacin in developing countries

Pediatric Infectious Disease Journal

Volumn 16, Issue 1, 1997, Pages 150-162

  Green, Stephen ^a   Tillotson, Glenn ^b  

^a ST LUKE S HOSPITAL   (United Kingdom)

^b Bayer plc UK   (United Kingdom)

Author keywords

cholera; Ciprofloxacin; developing countries; Escherichia coli gastroenteritis; meningococcal prevention; salmonellosis; shigellosis

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; ENOXACIN; MINOCYCLINE; NALIDIXIC ACID; NORFLOXACIN; RIFAMPICIN;

AFRICA; ANTIBIOTIC THERAPY; CHOLERA; CLINICAL TRIAL; CONFERENCE PAPER; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; GASTROINTESTINAL INFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; META ANALYSIS; NEISSERIA MENINGITIDIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHIGELLOSIS; SOCIOECONOMICS;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CHILD; CIPROFLOXACIN; DEVELOPING COUNTRIES; DIGESTIVE SYSTEM; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; GASTROINTESTINAL DISEASES; HUMANS;

EID: 0031058709     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199701000-00041     Document Type: Conference Paper

References (79)

1. Book of Vital World Statistics. The economist. London, UK: Hutchison, 1992.
2. Farthing MJG, Keusch GT. Global impact and patterns of intestinal infection. In: Farthing MJG, Keusch GT, eds. Enteric infection: mechanisms, manifestations and management. London: Chapman & Hall, 1989.
3. Felmingham D, Robbins MJ. In vitro activity of lomefloxacin and other antimicrobials against bacterial enteritis pathogens. Diagn Microbiol Infect Dis 1992;15:339-43.
4. Moore PS. Meningococcal meningitis in sub-Saharan Africa: a model for the epidemic process. Clin Infect Dis 1992;14:515-25.
5. Cuevas LE, Hart CA. Bacterial meningitis in Malawi. Malawi Med J 1991;7:2-6.
6. Hart CA, Cuevas LE. Chemoprophylaxis of meningococcal disease. J Med Microbiol 1993;39:15-7.
7. Shanahan PMA, Thomson CJ, Amyes SGB. The global impact of antibiotic-resistant bacteria: their sources and reservoirs. Rev Med Microbiol 1994;5:174-82.
8. Murray BE, DuPont HL. New antimicrobial agents and drug resistance. In: Farthing MJG, Keusch GT, eds. Enteric infections: mechanisms, manifestations and management. London: Chapman and Hall, 1989.
9. Tanaka T, Mitsuhashi S, eds. Microbial drug resistance. Tokyo: University Park Press, University of Tokyo, 1975.
10. Gangarosa EJ, Bennett JV, Wyatt C, et al. An epidemic-associated episome. J Infect Dis 1972;126:215-8.
11. Rowe B, Threlfall EJ. Drug resistance in Gram-negative aerobic bacilli. Br Med Bull 1984;40:68-76.
12. Fontaine O. Antibiotics in the management of shigellosis in children: what role for the quinolones? Rev Infect Dis 1989; 11(Suppl 5):S1145-50.
13. Tauxe RU, Puhr ND, Wells JG, et al. Antimicrobial resistance of shigella isolates in the USA: the importance of international travel. J Infect Dis 1990;162:1107-11.
14. Huq MI, Ahmed QS, Rahaman MH. Special publication No. 20. Dacca, Bangladesh: International Centre for Diarrheal Disease Research, 1983.
15. Murray BE. Resistance of Shigella, Salmonella and other selected enteric pathogens to antimicrobial agents. Rev Infect Dis 1986;8:S172-81.
16. Bennish ML, Salam MA, Hossain MA, et al. Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim/sulfamethoxazole and nalidixic acid. Clin Infect Dis 1992;14:1055-60.
17. Lolekha S, Vibuldandhitkit S, Poonyarrt P. Response to antimicrobial therapy for shigellosis in Thailand. Rev Infect Dis 1991;13:S342-6.
18. Adeleye LA, Adetosoye AI. Antimicrobial resistance patterns and plasmid survey of Salmonella and Shigella isolated in Ibadan, Nigeria. East Afr Med J 1993:259-62.
19. Kariuki S, Gilks C, Brindle R, et al. Antimicrobial susceptibility and presence of extrachromomosomal deoxyribonucleic acid in Salmonella and Shigella isolates from patients with AIDS. East Afr Med J 1994:292-6.
20. Mitra AK, Kabir I, Hossain MA. Pivmecillinam resistant Shigella dysenteriae: I. Infection in Bangladesh. Lancet 1990; 335:1461-2.
21. Schaad UB, Wedgwood-Krucko J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection 1987;15:165-8.
22. Haltalen KC, Nelson JD, Kusmiesz HT. Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis. Arch Dis Child 1973;48:305-12.
23. Hansson HB, Barkenius G, Cronberg S, Juhlia I. Controlled comparison of nalidixic acid or lactulose with placebo in shigellosis. Scand J Infect Dis 1981;13:191-3.
24. Rogerie F, Ott D, Vandepitte I, Verbist L, Lemmens P, Habiyaremye I. Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type I in adults. Antimicrob Agents Chemother 1986;29: 883-6.
25. De Mol P, Mets T, Lagasse R, Vandepitte J, Mutwewingabo A, Butcher JP. Treatment of bacillary dysentery: a comparison of between enoxacin and nalidixic acid. J Antimicrob Chemother 1987;19:695-8.
26. Salam MA, Bennish ML. Therapy for shigellosis: I. Randomized double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr 1989;113:901-7.
27. Gotuzo E, Oberhelman RA, Maguina C, et al. Comparison of single-dose treatment with norfloxacin and standard 5 day treatment with trimethoprim-sulfamethoxazole for acute shigellosis in adults. Antimicrob Agents Chemother 1989;33: 1101-4.
28. Bennish ML, Salam MA, Haider R, Barza M. Therapy for shigellosis: II. Randomized, double-blind comparisons of ciprofloxacin and ampicillin. J Infect Dis 1990;162:711-6.
29. Bennish ML, Salam MA, Khan WA, Khan AM. Treatment of shigellosis: III. Comparisons of one or two dose ciprofloxacin with standard 5 day therapy. Ann Intern Med 1992;177:727-34.
30. Slack RB. Escherichia coli infections. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. Philadelphia: Saunders, 1992.
31. Merson MH, Black RE. Enterotoxigenic Escherichia coli diarrhoea. In: Holme T, Holmgren J, Merson MH, Mollby R, eds. Acute enteric infections in children: new prospects for treatment and prevention. Amsterdam: Elsevier-North Holland, 1981.
32. Levine MM, Bergquist EJ, Nalin DR, et al. Escherichia coli strains that cause diarrhoea but do not produce heat labile or heat stable enterotoxins and are non-invasive. Lancet 1978; 1:1119-22.
33. Rothbaum R, McAdams AJ, Gianella R, et al. A clinicopathologic study of enterocyte adherent Escherichia coli, a cause of protracted diarrhoea in infants. Gastroenterology 1982;83: 441-54.
34. Riley LW, Remis RS, Helgerson SD, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 1983;308:681-5.
35. Bandres JC, DuPont HL. Approach to the patient with diarrhoea. In: Gorbach SL Bartlett JG, Blacklow NR, eds. Infectious disease. Philadelphia: Saunders, 1992.
36. Lester SC, Pilar P, Wang F, et al. The carriage of Escherichia coli resistant to antimicrobial agents by healthy children in Boston, in Caracas, Venezuela and in Qin Pu, China. N Engl J Med 1990;323:285-9.
37. Taylor DN, Sanchez JL, Candler W, et al. Treatment of travellers' diarrhoea, ciprofloxacin plus loperamide compared with ciprofloxacin alone: a placebo controlled randomized trial. Ann Intern Med 1991;114:731-4.
38. Gillespie SH, Fox R, Patel S, et al. Antibiotic susceptibility of Enterobacteriaceae isolated from patients in Northern Tanzania. J Antimicrob Chemother 1992;29:227-9.
39. Gorbach SL. Travellers diarrhoea. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. Philadelphia: Saunders, 1992.
40. Salam I, Katelavis P, Leigh-Smith S, Farthing MJG. Randomized trial of single-dose ciprofloxacin for travellers diarrhea. Lancet 1994;344:1537-9.
41. Holmberg SD. Cholera and related illnesses caused by Vibrio species and Aeromonas. In: Gorbach SL, Barlett JG, Blacklow NR, eds. Infectious diseases. Philadelphia: Saunders, 1992.
42. Morris JG, Black RE. Cholera and other vibrioses in the United States. N Engl J Med 1985;312:343-50.
43. World Health Organisation Cholera Surveillance. Multiply antibiotic resistant O-group I Vibrio cholerae. Wkly Epidemiol Rec 1980;38:292-3.
44. Khan WA, Sears S, Khan EH, Salam MA, Bennish ML. Randomized double-blinded comparison of single dose ciprofloxacin with single dose doxycycline in the treatment of Vibrio cholerae O139 (Bengal) infection [Abstract M51]. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 4 to 7, 1994, Orlando, Fla.
45. Gotuzo E, Carillo C, Echevarra J, et al. Efficacy and tolerance of ciprofloxacin as prophylaxis treatment in family members of patients with cholera diarrhea (Peru, 1993) [Abstract 1028]. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1993, October 17 to 20, New Orleans, LA.
46. Cochi SL, Markowitz LE, Joshi DD. Control of epidemic Group A meningococcal meningitis in Nepal. Int J Epidemic 1987;16:91-7.
47. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against Group B meningococcal disease in Norway. Lancet 1991;338:1093-6.
48. Centers for Disease Control. Meningococcal disease surveillance group analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. J Infect Dis 1976;134:201-4.
49. Cooper ER, Ellison RT, Smith GS, et al. Rifampicin-resistant meningococcal disease in a contact patient given prophylactic rifampicin. J Pediatr 1986;108:93-6.
50. Schwartz B, Al-Tabaiqi A, Al-Ruwais A, et al. Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of Group A Neisseria meningitidis. Lancet 1988;1:1239-42.
51. Gaunt PN, Lambert BE. Single-dose ciprofloxacin for the eradication of pharyngeal carriage of Neisseria meningitidis. J Antimicrob Chemother 1988;21:489-96.
52. Dworzack DL, Sanders CC, Horowitz EA, et al. Evaluation of single dose ciprofloxacin in the eradication of Neisseria meningitidis from nasopharyngeal carriers. Antimicrob Agents Chemother 1988;32:1740-1.
53. Cuevas LE, Kazembe P, Mughogho GK, et al. Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin. J Infect Dis 1995;171:728-31.
54. Pugsley MP, Dworzack DL, Roccaforte JS, et al. An open study of the efficacy of a single dose of ciprofloxacin in eliminating the chronic nasopharyngeal carriage of Neisseria meningitidis. J Infect Dis 1988;157:852-3.
55. St Gerne J, Hodes HL, Marcy SM, et al. Consensus: management of Salmonella infection in the first year of life. Pediatr Infect Dis J 1988;7:615-21.
56. Maiorini E, Lopez EL, Morrow AL, et al. Multiply resistant nontyphoidal Salmonella gastroenteritis in children. Pediatr Infect Dis J 1993;12:139-44.
57. Mabey DCW, Brown A, Greenwood BM. Plasmodium falciparum malaria and Salmonella infections in Gambian children. J Infect Dis 1987;155:1319-21.
58. Gendrel D, Kombila M, Beaudoin-Leblevec G, Richard-Lenoble D. Nontyphoidal Salmonella septicaemia in Gabonese children infected with Schistosoma intercalatum. Clin Infect Dis 1994;18:103-5.
59. Mallouh AA, Salamah MM. Pattern of bacterial infections in homozygous sickle cell disease, a report from Saudi Arabia. Am J Dis Child 1985;139:820-2.
60. Lepage P, Bogaerts J, Van Goethem M, et al. Community acquired bacteraemia in African children. Lancet 1987:1458-61.
61. Weeramanthi TS, Corrah PT, Mabey DCW, Greenwood BM. Clinical experiences with enteric fever in the Gambia, West Africa 1981-1986. J Trop Med Hyg 1989;92:272-5.
62. Nesbitt A, Mirza NB. Salmonella septicaemias in Kenyan children. J Trop Paediatr 1989;35:35-9.
63. Hadfield TL, Menson MH, Wachsmith IK. An outbreak of antibiotic-resistant Salmonella enteritidis in Liberia, West Africa. J Infect Dis 1985;151:790-5.
64. Saha MR, Dutta P, Bhattacharya SK, et al. Occurrence of multi-drug resistance Salmonella typhi in Calcutta. Indian J Med Res 1992;95:179-80.
65. Dar L, Gupta BL, Rattan A, et al. Multidrug resistant Salmonella typhi in Delhi. Indian J Pediatr 1992;59:221-4.
66. Amand AC, Kataria VK, Singh W, Chatterjee SK. Epidemic multi-resistant enteric fever in Eastern India [Letter]. Lancet 1990;335:352.
67. Mashako MNL, Luki N, Nsibu N, et al. Les infections a Salmonella a Kinshasa: especes en cause et sensibilité aux antibiotiques. Pediatrie 1991;46:691-6.
68. Berkowitz FE. Bacteraemia in hospitalized black South African children. Am J Dis Child 1984;138:551-6.
69. Pape JW, Gerdes H, Oriol L, et al. Typhoid fever: successful therapy with cefoperazone. J Infect Dis 1986;153:272-6.
70. Ti T, Monteiro EH, Lam S, et al. Ceftriaxone therapy in bacteremic typhoid fever. Antimicrob Agents Chemother 1985;28:540-3.
71. Ramirez CA, Bran JL, Mejia CR, et al. Open, prospective study of the clinical efficacy of ciprofloxacin. Antimicrob Agents Chemother 1985;28:128-32.
72. Gendrel D, Raymond J, Legall MA, et al. Use of pefloxacin after failure of initial antibiotic treatment in children with severe salmonellosis. Eur J Clin Microbiol Infect Dis 1993; 12:209-11.
73. Dutta P, Rasaily R, Saha MR, et al. Ciprofloxacin treatment of severe typhoid fever in children. Antimicrob Agents Chemother 1993;37:1197-9.
74. Ericsson CD, Johnson PC, DuPont HL, et al. Ciprofloxacin or trimethoprim/sulfamethoxazole as initial therapy for traveler's diarrhea: a placebo-controlled, randomized trial. Ann Intern Med 1987;106:216-20.
75. Green SDR, Ilunga FI, Cheesborough JS, et al. The treatment of neonatal meningitis due to Gram-negative bacilli with ciprofloxacin: evidence of satisfactory penetration into the cerebrospinal fluid. J Infect 1993;26:253-6.
76. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991;91:462-70.
77. Narendranathan M, George TP. Chloramphenicol and ciprofloxacin in enteric fever cost-effectiveness. J Assoc Phys India 1992;40:176-8.
78. Farrar WE. Antibiotic resistance in developing countries. J Infect Dis 1985;152:1103-6.
79. Rosenstiel N, Adam D. Quinolone antibacterials: an update of their pharmacology and therapeutic use. Drugs 1994;47:872-901.